Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue from product sales	$ 0	$ 215,000	$ 0	$ 300,000
Collaboration revenue	0	0	0	18,000
Total revenue	0	215,000	0	318,000
Cost of product sales	0	287,000	0	696,000
Cost of collaboration revenue	0	0	0	1,000
Total cost of revenue	0	287,000	0	697,000
Gross loss	0	(72,000)	0	(379,000)
Research and development expense	1,657,000	1,645,000	4,800,000	6,599,000
Selling, general and administrative expense	1,958,000	2,723,000	5,109,000	8,003,000
Intangible asset impairment expense	0	0	0	3,905,000
Restructuring costs	0	43,000	0	335,000
Operating loss	(4,596,000)	(5,017,000)	(14,077,000)	(22,004,000)
Other income (expense):
Warrant revaluation income (expense)	4,981,000	3,007,000	(4,742,000)	10,518,000
Derivative revaluation income (expense)	(254,000)	(251,000)	287,000	(251,000)
Interest expense	(273,000)	(46,000)	(641,000)	(46,000)
Other income (expense), net	27,000	8,000	33,000	(15,000)
Loss before income taxes	(115,000)	(2,299,000)	(19,140,000)	(11,798,000)
Income taxes	0	0	0	0
Net loss	(115,000)	(2,299,000)	(19,140,000)	(11,798,000)
Dividend paid in-kind to preferred stockholders	(82,000)	0	(182,000)	0
Deemed dividend on preferred stock (see Note 10)	(111,000)	0	(3,981,000)	0
Net loss attributable to common stockholders	$ (308,000)	$ (2,299,000)	$ (23,303,000)	$ (11,798,000)
Per Share Information:
Basic net loss (usd per share)	$ (0.02)	$ (0.16)	$ (1.58)	$ (0.81)
Diluted net loss (usd per share)	$ (0.02)	$ (0.16)	$ (1.58)	$ (0.94)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding (shares)	14,717,043	14,632,988	14,702,624	14,632,988
Diluted weighted average number of common shares outstanding (shares)	14,733,318	14,632,988	14,702,624	14,640,996
Affiliated Entity
Research and development expense	$ 981,000	$ 534,000	$ 4,168,000	$ 2,783,000